SAN DIEGO & INDIANAPOLIS & WALTHAM, Mass., Feb 25, 2010 (BUSINESS WIRE) -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company
(NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) today confirmed that the
U.S. Food and Drug Administration (FDA) has set a new Prescription Drug
User Fee Act (PDUFA) action date of March 12 for its review of the
exenatide once weekly new drug application (NDA). The revised action
date is the result of the FDA's decision to allow five additional days
for its review of pending regulatory applications following the agency's
recent five-day weather-related closure.
Exenatide once weekly is an investigational, extended-release medication
for type 2 diabetes designed to deliver continuous therapeutic levels of
exenatide in a single weekly dose. The NDA for exenatide once weekly was
submitted in May 2009 and accepted by the FDA in July 2009.
Additional information about weather-related delays is available in a
press release on the FDA's Web site: http://www.fda.gov/ForIndustry/UserFees/PrescriptionDrugUserFee/ucm200361.htm.
About Amylin, Lilly and Alkermes
Amylin, Lilly and Alkermes are working together to develop exenatide
once weekly, a subcutaneous injection of exenatide for the treatment of
type 2 diabetes based on Alkermes' proprietary Medisorb(R) technology
for long-acting medications. Exenatide once weekly is not currently
approved by any regulatory agencies.
Amylin Pharmaceuticals is a biopharmaceutical company dedicated to
improving lives of patients through the discovery, development and
commercialization of innovative medicines. Amylin's research and
development activities leverage the Company's expertise in metabolism to
develop potential therapies to treat diabetes and obesity. Amylin is
headquartered in San Diego, California.
Through a long-standing commitment to diabetes care, Lilly provides
patients with breakthrough treatments that enable them to live longer,
healthier and fuller lives. Since 1923, Lilly has been the industry
leader in pioneering therapies to help healthcare professionals improve
the lives of people with diabetes, and research continues on innovative
medicines to address the unmet needs of patients.
Lilly, a leading innovation-driven corporation, is developing a growing
portfolio of pharmaceutical products by applying the latest research
from its own worldwide laboratories and from collaborations with eminent
scientific organizations. Headquartered in Indianapolis, Indiana, Lilly
provides answers - through medicines and information - for some of the
world's most urgent medical needs.
Alkermes, Inc. is a fully integrated biotechnology company committed to
developing innovative medicines to improve patients' lives. Alkermes'
robust pipeline includes extended-release injectable, pulmonary and oral
products for the treatment of prevalent, chronic diseases, such as
central nervous system disorders, addiction and diabetes. Headquartered
in Waltham, Massachusetts, Alkermes has a research facility in
Massachusetts and a commercial manufacturing facility in Ohio.
Medisorb(R) is a registered trademark of Alkermes, Inc.
SOURCE: Alkermes, Inc. and Amylin Pharmaceuticals, Inc. and Eli Lilly and Company
Amylin - Anne Erickson
Phone: (858) 754-4443
Cell: (858) 349-3195
Lilly - Kindra Strupp
Phone: (317) 277-5170
Cell: (317) 554-9577
Alkermes - Rebecca Peterson
Phone: (781) 609-6378
Cell: (617) 899-2447